Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindi, V. I.
Right arrow Articles by Tuomilehto, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindi, V. I.
Right arrow Articles by Tuomilehto, J.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2581-2586, 2002
© 2002 by the American Diabetes Association, Inc.

Association of the Pro12Ala Polymorphism in the PPAR-{gamma}2 Gene With 3-Year Incidence of Type 2 Diabetes and Body Weight Change in the Finnish Diabetes Prevention Study

Virpi I. Lindi1, Matti I.J. Uusitupa1, Jaana Lindström2, Anne Louheranta1, Johan G. Eriksson2, Timo T. Valle2, Helena Hämäläinen3, Pirjo Ilanne-Parikka4, Sirkka Keinänen-Kiukaanniemi5, Markku Laakso6, and Jaakko Tuomilehto7 for the Finnish Diabetes Prevention Study Group

1 Department of Clinical Nutrition, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
2 Department of Epidemiology and Health Promotion, Diabetes and Genetic Epidemiology Unit, National Public Health Institute, Helsinki, Finland
3 Social Insurance Institution, Research and Development Centre, Turku, Finland
4 Department of Medicine, University of Tampere and Finnish Diabetes Association, Tampere, Finland
5 Department of Public Health Science and General Practice, University of Oulu, Oulu University Hospital, and the Department of Sports Medicine, Oulu Deaconess Institute, Oulu, Finland
6 Department of Medicine, University of Kuopio, Kuopio, Finland
7 Department of Public Health, University of Helsinki, Helsinki, Finland

The association of the Pro12Ala polymorphism of the PPAR-{gamma}2 gene with the incidence of type 2 diabetes was investigated in 522 subjects with impaired glucose tolerance (IGT) participating in the Finnish Diabetes Prevention Study. Subjects were randomized to either an intensive diet and exercise group or a control group. By 3 years of intervention, the odds ratio of the development of type 2 diabetes for subjects with the Ala12 allele was 2.11-fold compared with that for subjects with the Pro12Pro genotype (95% CI 1.20–3.72). The risk for type 2 diabetes increased also in subjects who gained weight or belonged to the control group. In the intervention group, subjects with the Ala12Ala genotype lost more weight during the follow-up than subjects with other genotypes (Pro12Pro vs. Ala12Ala P = 0.043), and none of subjects with the Ala12Ala genotype developed type 2 diabetes in this group. In conclusion, the Ala12 allele may predispose to the development of type 2 diabetes in obese subjects with IGT. However, beneficial changes in diet, increases in physical activity, and weight loss may reverse, to some extent, the diabetogenic impact of the Ala12 allele, possibly due to an improved insulin sensitivity.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
J. Waden, L. M. Thorn, C. Forsblom, T. Lakka, M. Saraheimo, M. Rosengard-Barlund, O. Heikkila, M. Wessman, J. A. Turunen, M. Parkkonen, et al.
Leisure-Time Physical Activity Is Associated With the Metabolic Syndrome in Type 1 Diabetes: Effect of the PPAR{gamma} Pro12Ala polymorphism: the FinnDiane Study
Diabetes Care, June 1, 2007; 30(6): 1618 - 1620.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. C. Florez, K. A. Jablonski, M. W. Sun, N. Bayley, S. E. Kahn, H. Shamoon, R. F. Hamman, W. C. Knowler, D. M. Nathan, D. Altshuler, et al.
Effects of the Type 2 Diabetes-Associated PPARG P12A Polymorphism on Progression to Diabetes and Response to Troglitazone
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1502 - 1509.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. Tonjes, M. Scholz, M. Loeffler, and M. Stumvoll
Association of Pro12Ala Polymorphism in Peroxisome Proliferator-Activated Receptor {gamma} With Pre-Diabetic Phenotypes: Meta-analysis of 57 studies on nondiabetic individuals.
Diabetes Care, November 1, 2006; 29(11): 2489 - 2497.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
F. Soriguer, S. Morcillo, F. Cardona, G. Rojo-Martinez, M. de la Cruz Almaraz, M. de la Soledad Ruiz de Adana, G. Olveira, F. Tinahones, and I. Esteva
Pro12Ala Polymorphism of the PPARG2 Gene Is Associated with Type 2 Diabetes Mellitus and Peripheral Insulin Sensitivity in a Population with a High Intake of Oleic Acid
J. Nutr., September 1, 2006; 136(9): 2325 - 2330.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Jaziri, S. Lobbens, R. Aubert, F. Pean, S. Lahmidi, M. Vaxillaire, I. Porchay, N. Bellili, J. Tichet, B. Balkau, et al.
The PPARG Pro12Ala Polymorphism Is Associated With a Decreased Risk of Developing Hyperglycemia Over 6 Years and Combines With the Effect of the APM1 G-11391A Single Nucleotide Polymorphism: The Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) Study.
Diabetes, April 1, 2006; 55(4): 1157 - 1162.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Sesti, L. Perego, M. Cardellini, F. Andreozzi, C. Ricasoli, P. Vedani, V. Guzzi, M. Marchi, M. Paganelli, G. Ferla, et al.
Impact of Common Polymorphisms in Candidate Genes for Insulin Resistance and Obesity on Weight Loss of Morbidly Obese Subjects after Laparoscopic Adjustable Gastric Banding and Hypocaloric Diet
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5064 - 5069.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Pischon, J. K. Pai, J. E. Manson, F. B. Hu, K. M. Rexrode, D. Hunter, and E. B. Rimm
Peroxisome Proliferator-Activated Receptor-{gamma}2 P12A Polymorphism and Risk of Coronary Heart Disease in US Men and Women
Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1654 - 1658.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Vanttinen, P. Nuutila, J. Pihlajamaki, K. Hallsten, K. A. Virtanen, R. Lautamaki, P. Peltoniemi, J. Kemppainen, T. Takala, A. P. M. Viljanen, et al.
The Effect of the Ala12 Allele of the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene on Skeletal Muscle Glucose Uptake Depends on Obesity: A Positron Emission Tomography Study
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4249 - 4254.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
ABDOMINAL OBESITY STUDY GROUP, F. E. VON EYBEN, J. P. KROUSTRUP, J. F. LARSEN, and J. CELIS
Comparison of Gene Expression in Intra-Abdominal and Subcutaneous Fat: A Study of Men with Morbid Obesity and Nonobese Men Using Microarray and Proteomics
Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 508 - 536.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. Knouff and J. Auwerx
Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Endocr. Rev., December 1, 2004; 25(6): 899 - 918.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. S. Tai, D. Corella, M. Deurenberg-Yap, X. Adiconis, S. K. Chew, C. E. Tan, and J. M. Ordovas
Differential effects of the C1431T and Pro12Ala PPAR{gamma} gene variants on plasma lipids and diabetes risk in an Asian population
J. Lipid Res., April 1, 2004; 45(4): 674 - 685.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Ferrannini, M. Nannipieri, K. Williams, C. Gonzales, S. M. Haffner, and M. P. Stern
Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance
Diabetes, January 1, 2004; 53(1): 160 - 165.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Memisoglu, F. B. Hu, S. E. Hankinson, J. E. Manson, I. De Vivo, W. C. Willett, and D. J. Hunter
Interaction between a peroxisome proliferator-activated receptor {gamma} gene polymorphism and dietary fat intake in relation to body mass
Hum. Mol. Genet., November 15, 2003; 12(22): 2923 - 2929.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
S Masud and S Ye
Effect of the peroxisome proliferator activated receptor-{gamma} gene Pro12Ala variant on body mass index: a meta-analysis
J. Med. Genet., October 1, 2003; 40(10): 773 - 780.
[Full Text] [PDF]


Home page
DiabetesHome page
W.H. L. Kao, J. Coresh, A. R. Shuldiner, E. Boerwinkle, M. S. Bray, and F. L. Brancati
Pro12Ala of the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Is Associated With Lower Serum Insulin Levels in Nonobese African Americans: The Atherosclerosis Risk in Communities Study
Diabetes, June 1, 2003; 52(6): 1568 - 1572.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
O. Tschritter, A. Fritsche, F. Shirkavand, F. Machicao, H. Haring, and M. Stumvoll
Assessing the Shape of the Glucose Curve During an Oral Glucose Tolerance Test
Diabetes Care, April 1, 2003; 26(4): 1026 - 1033.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.